PEG‐asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol
Pediatric Blood & Cancer2014Vol. 62(3), pp. 427–433
Citations Over TimeTop 10% of 2014 papers
Louise Tram Henriksen, Arja Harila‐Saari, Ellen Ruud, Jonas Abrahamsson, Kaie Pruunsild, Goda Vaitkevičienė, Ólafur Gísli Jónsson, Kjeld Schmiegelow, Mats Heyman, Henrik Daa Schrøder, Birgitte Klug Albertsen, on behalf of the Nordic Society of Paediatric Haematology and Oncology (NOPHO) group
Abstract
Clinical allergy to PEG-asparaginase occurred early in treatment, was in general moderate in severity, and mostly developed within 2 hr after PEG-asparaginase administration. The risk of subsequent Erwinase allergic reactions was low.
Related Papers
- → Monitoring asparaginase activity to improve the management of patients with acute lymphoblastic leukemia: Experience in one center(2024)2 cited
- → Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study(2016)9 cited
- [Repeated treatment with L-asparaginase of acute lymphoblastic leukemia in children].(1974)
- → How do different regimens of PEG-asparaginase affect outcomes in children and adolescents with acute lymphoblastic leukemia (ALL)?(2023)
- → Comparison of the Effects of L-asparaginase and Pegaspargase in the Treatment of Adult Acute Lymphoblastic Leukemia(2023)